Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31753754 | 1.00 | CYP4F2 (0.54) | CYP4F2CYP4A11LOXL2ALDH1A1CYP3A4 | |
| SCHEMBL16799629 | 0.92 | CYP4A11 (0.55) | CYP4F2CYP4A11LOXL2ALDH1A1CYP3A4 | |
| SCHEMBL31753430 | 0.92 | CYP4A11 (0.55) | CYP4F2CYP4A11LOXL2ALDH1A1CYP3A4 | |
| SCHEMBL5663849 | 0.88 | CYP4F2 (0.53) | CYP4F2CYP4A11LOXL2ALDH1A1CYP3A4 | |
| SCHEMBL24358827 | 0.85 | MAPK1 (0.43) | CYP4F2CYP4A11LOXL2ALDH1A1CYP3A4 | |
| SCHEMBL16799938 | 0.83 | LOXL2 (0.43) | CYP4F2CYP4A11LOXL2ALDH1A1CYP3A4 | |
| SCHEMBL16799587 | 0.83 | ALDH1A1 (0.47) | CYP4F2CYP4A11LOXL2ALDH1A1CYP3A4 | |
| SCHEMBL20810526 | 0.82 | LOXL2 (0.43) | CYP4F2CYP4A11LOXL2ALDH1A1CYP3A4 | |
| SCHEMBL3458276 | 0.81 | PTPN11 (0.51) | CYP4F2CYP4A11LOXL2ALDH1A1TSHR | |
| SCHEMBL46622 | 0.81 | ASIC3 (0.48) | MAPK14ASIC3CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| US-11078214-B2 | Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-08-03 | — | — | US | disclosed |
| US-10457688-B2 | Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-10-29 | — | — | US | disclosed |
| US-9994586-B2 | Monocyclic, thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of the same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994586-B2 | Monocyclic, thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of the same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-06-12 | — | — | US | disclosed |
| WO-2017031176-A1 | MONOCYCLIC, THIENO, PYRIDO, AND PYRROLO PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE OF THE SAME | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170050978-A1 | Monocyclic, Thieno, Pyrido, and Pyrrolo Pyrimidine Compounds and Methods of Use and Manufacture of the Same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2017-02-23 | — | — | US | disclosed |
| US-20170050978-A1 | Monocyclic, Thieno, Pyrido, and Pyrrolo Pyrimidine Compounds and Methods of Use and Manufacture of the Same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2017-02-23 | — | — | US | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | CYP4F2 352/4885CYP4A11 1282/4885LOXL2 4391/4885 |
| US-11078214-B2 | Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same | DPYD, TYMS, THPO | CYP4F2 121/4885CYP4A11 189/4885LOXL2 3093/4885 |
| US-10457688-B2 | Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same | DPYD, TPX2, TYMS | CYP4F2 214/4885CYP4A11 384/4885LOXL2 3841/4885 |
| US-20170050978-A1 | Monocyclic, Thieno, Pyrido, and Pyrrolo Pyrimidine Compounds and Methods of Use and Manufacture of the Same | CYP4F3, TYMS, DPYD | CYP4F2 19/4885CYP4A11 443/4885LOXL2 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.